At the 61st ASH Annual Meeting & Exposition, Srdan Verstovsek, Anderson Cancer Center, discusses his presentation on Approaches to the Individualized Management of Myeloproliferative Neoplasms: Best Practices and Guidance to Optimize Care.
Questions
1. What impact has molecular profiling had on the prognostication and treatment of myeloproliferative neoplasms (MPNs)? (0:05)
2. What is the rationale for risk-adapted therapy for patients with essential thrombocythemia (ET) and polycythemia vera (PV)? (1:47)
3. What are the most important emerging therapies for MPNs? (3:12)
4. What factors should be considered when selecting the most appropriate treatment for an individual? (4:43)
5. How can we best manage treatment-related toxicities and optimise dosing regimens? (6:24)
Srdan Verstovsek has no conflicts of interest to declare in relation to this video.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
